FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2290702923> ?p ?o ?g. }

• W2290702923 endingPage "iv247" @default.
• W2290702923 startingPage "iv247" @default.
• W2290702923 abstract "ABSTRACT Aim: TACE is associated with an upregulation of VEGF leading to revascularization. Axitinib is a potent and selective inhibitor of VEGFR1, 2 and 3. We hypothesized that the addition of axitinib to TACE has synergistic activity by abolishing the VEGF driven signal after TACE. To prove this concept, we designed a phase II study to evaluate the efficacy and safety of the combination for treatment of inoperable HCC. Methods: This is an investigator-initiated phase II single-arm study. The target sample size is 50. Key eligibility criteria include confirmed diagnosis of inoperable HCC; Child's A liver function; ECOG PS 0-2; absence of prior systemic nor TACE treatment; the absence of main portal vein thrombosis or distant metastases. Treatment consists of 8 weekly cycle of axitinib 5mg twice daily. In each cycle, TACE is administered at 5th week when there is radiologically viable tumour and absence of ≥grade 3 toxicity from axitinib. Axitinib is withheld 24h before each TACE, and resumed 24h after TACE when patients (pts) have preserved liver function. Reassessment imaging is done every 8 weeks. In the 1st year, each pt is treated with a maximum number of 6 cycles of TACE. Pt is put on maintenance axitinib alone if there is no PD after 1 year. Results: Total 50 pts have been accrued. Baseline characteristics: BCLC stage B 38; C 12. Median age 62.1years. At the time of data cutoff on 17 Apr 2014, the median follow-up was 1.32 years. 27 pts have PD, and the median TTP is 10.4 months (95% CI = 5.43-13.72). The median OS is 15.9 months (95% CI = 12.9-not reached). Amongst 42 evaluable pts, the response rate (mRECIST) is 48.8% (7 CR; 14 PR) and the disease control rate is 88.4% (21 CR/PR and 16 SD). Amongst the responders, 3 pts underwent hepatectomy after shrinkage of tumour, and surgical specimen showed extensive tumour necrosis; 2 pts just had portal vein embolization to induce left lobe hypertrophy, and is currently wait-listed for hepatectomy. Total 5 pts could proceed to the axitinib maintenance phase. Common ≥grade 3 toxicity events from axitinib include hypertension (20%), hand foot skin reaction (10%), fatigue (4%) and hyperbilirubinaemia (4%). The toxicity of TACE is not worsened by axitinib. Conclusions: Combination of axitinib and TACE is associated with high tumour response rate and efficacy in unresectable HCC. Further evaluation with randomized study is indicated. (NCT01352728) Disclosure: S.L. Chan: received research funding from Pfizer. All other authors have declared no conflicts of interest." @default.
• W2290702923 created "2016-06-24" @default.
• W2290702923 creator A5000280270 @default.
• W2290702923 creator A5023086891 @default.
• W2290702923 creator A5025112401 @default.
• W2290702923 creator A5028553204 @default.
• W2290702923 creator A5040501590 @default.
• W2290702923 creator A5042999144 @default.
• W2290702923 creator A5043148694 @default.
• W2290702923 creator A5046498356 @default.
• W2290702923 creator A5048812777 @default.
• W2290702923 creator A5081429361 @default.
• W2290702923 creator A5085444884 @default.
• W2290702923 date "2014-09-01" @default.
• W2290702923 modified "2023-10-17" @default.
• W2290702923 title "A Phase Ii Study on Combination of Axitinib and Transarterial Chemoembolization (Tace) for Treatment of Inoperable Hepatocellular Carcinoma (Hcc)" @default.
• W2290702923 doi "https://doi.org/10.1093/annonc/mdu334.115" @default.
• W2290702923 hasPublicationYear "2014" @default.
• W2290702923 type Work @default.
• W2290702923 sameAs 2290702923 @default.
• W2290702923 citedByCount "1" @default.
• W2290702923 countsByYear W22907029232022 @default.
• W2290702923 crossrefType "journal-article" @default.
• W2290702923 hasAuthorship W2290702923A5000280270 @default.
• W2290702923 hasAuthorship W2290702923A5023086891 @default.
• W2290702923 hasAuthorship W2290702923A5025112401 @default.
• W2290702923 hasAuthorship W2290702923A5028553204 @default.
• W2290702923 hasAuthorship W2290702923A5040501590 @default.
• W2290702923 hasAuthorship W2290702923A5042999144 @default.
• W2290702923 hasAuthorship W2290702923A5043148694 @default.
• W2290702923 hasAuthorship W2290702923A5046498356 @default.
• W2290702923 hasAuthorship W2290702923A5048812777 @default.
• W2290702923 hasAuthorship W2290702923A5081429361 @default.
• W2290702923 hasAuthorship W2290702923A5085444884 @default.
• W2290702923 hasBestOaLocation W22907029231 @default.
• W2290702923 hasConcept C126322002 @default.
• W2290702923 hasConcept C126838900 @default.
• W2290702923 hasConcept C143998085 @default.
• W2290702923 hasConcept C2776539811 @default.
• W2290702923 hasConcept C2777546739 @default.
• W2290702923 hasConcept C2778019345 @default.
• W2290702923 hasConcept C2778695046 @default.
• W2290702923 hasConcept C71924100 @default.
• W2290702923 hasConcept C90924648 @default.
• W2290702923 hasConceptScore W2290702923C126322002 @default.
• W2290702923 hasConceptScore W2290702923C126838900 @default.
• W2290702923 hasConceptScore W2290702923C143998085 @default.
• W2290702923 hasConceptScore W2290702923C2776539811 @default.
• W2290702923 hasConceptScore W2290702923C2777546739 @default.
• W2290702923 hasConceptScore W2290702923C2778019345 @default.
• W2290702923 hasConceptScore W2290702923C2778695046 @default.
• W2290702923 hasConceptScore W2290702923C71924100 @default.
• W2290702923 hasConceptScore W2290702923C90924648 @default.
• W2290702923 hasLocation W22907029231 @default.
• W2290702923 hasOpenAccess W2290702923 @default.
• W2290702923 hasPrimaryLocation W22907029231 @default.
• W2290702923 hasRelatedWork W141524600 @default.
• W2290702923 hasRelatedWork W2155887765 @default.
• W2290702923 hasRelatedWork W2597682599 @default.
• W2290702923 hasRelatedWork W2766588635 @default.
• W2290702923 hasRelatedWork W2889824748 @default.
• W2290702923 hasRelatedWork W3015396990 @default.
• W2290702923 hasRelatedWork W3029220886 @default.
• W2290702923 hasRelatedWork W4234150219 @default.
• W2290702923 hasRelatedWork W4240236077 @default.
• W2290702923 hasRelatedWork W4251581028 @default.
• W2290702923 hasVolume "25" @default.
• W2290702923 isParatext "false" @default.
• W2290702923 isRetracted "false" @default.
• W2290702923 magId "2290702923" @default.
• W2290702923 workType "article" @default.